Evidence map›Paper›PMID 36232859›Full record

ArticleInternational journal of molecular sciences2022

Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas.

Mario Sánchez-Canteli, Luis Juesas, Irati Garmendia, María Otero-Rosales, Alfonso Calvo, Monica Alvarez-Fernández, Aurora Astudillo, Luis M Montuenga, Juana M García-Pedrero, Juan P Rodrigo

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mario Sánchez-CanteliDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
Luis JuesasDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
Irati GarmendiaCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.ORCID 0000-0001-7124-6137
María Otero-RosalesDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.ORCID 0000-0003-3369-0821
Alfonso CalvoCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.ORCID 0000-0003-4074-4242
Monica Alvarez-FernándezDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.ORCID 0000-0002-6454-5128
Aurora AstudilloTumor Biobank, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.
Luis M MontuengaCentro de Investigación Biomedica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.ORCID 0000-0002-8739-1387
Juana M García-PedreroDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.ORCID 0000-0002-5891-9488
Juan P RodrigoDepartment of Otolaryngology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.ORCID 0000-0003-3063-0890
Universidad de Oviedo · ESCentro de Investigación Biomédica en Red de Cáncer · ES

Funding

Asociación Española Contra el Cáncer AECC; 2019/ INVES19001ALVACentro de Investigación Biomédica en Red de Cáncer CB16/12/00390Centro de Investigación Biomédica en Red de Cáncer CB16/12/00443Fundación Merck Salud 17-CC-008Gobierno del Principado de Asturias IDI/2021/000079Instituto de Salud Carlos III 16/00280Instituto de Salud Carlos III PI19/00098Instituto de Salud Carlos III PI19/00560
6 · The paper itself

Abstract

Activation of WNT/β-catenin signaling has been associated with a non-T-cell-inflamed tumor microenvironment (TME) in several cancers. The aim of this work was to investigate the relationship between β-catenin signaling and TME inflammation in head and neck squamous cell carcinomas (HNSCCs). Membrane and nuclear β-catenin expression, PD-L1 expression, and CD8+ tumor-infiltrating lymphocyte (TIL) density were jointly evaluated by immunohistochemistry in a series of 372 HPV-negative HNSCCs. Membrane β-catenin levels decreased in carcinomas compared to the normal epithelium. Positive nuclear β-catenin was detected in 50 tumors (14.3%) and was significantly associated with a low CD8+ TIL density (168 cells/mm

Indexed as

B7-H1 AntigenHead and Neck Neoplasmsbeta CateninCD8-Positive T-LymphocytesHumansLymphocytes, Tumor-InfiltratingPhenotypeSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentB7-H1 Antigenbeta Cateninhead and neckPD-L1squamous cell carcinomatumor infiltrating lymphocytesβ-catenin

Identifiers

PMID36232859
PMCPMC9569731
OpenAlexW4303699539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.